Latest Regulatory Risk News

Auris Minerals Limited has been queried by the ASX following a sharp rise in its share price and trading volume, with the company denying any undisclosed information behind the surge.

Ainsworth Game Technology has issued a Target's Statement responding to an unsolicited proportional takeover bid by Kjerulf David Hastings Ainsworth amid an ongoing full takeover offer from Novomatic. The Independent Board Committee refrains from recommending acceptance or rejection, highlighting complex shareholder choices.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

The Australian Competition and Consumer Commission has given the green light to Caterpillar’s proposed acquisition of RPMGlobal, clearing a major regulatory hurdle. The deal now awaits shareholder and Foreign Investment Review Board approvals.

Magellan Asset Management has launched the Magellan Infrastructure Fund (Currency Hedged), an actively managed ETF trading on the ASX under ticker MICH, targeting global listed infrastructure with currency hedging and ESG integration.

Somerset Minerals Limited has launched a C$2.25 million flow-through share offer targeting Canadian investors, aiming to accelerate exploration activities at its Jura project. The capital raise complements a planned institutional placement and highlights both growth ambitions and inherent risks.

Ampol Limited has launched a A$500 million delayed-draw subordinated notes facility, designed to fund its proposed acquisition of EG Australia and refinance existing debt, offering long-term capital with flexible issuance options.

Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.

FireFly Metals has launched a dual capital raising initiative, combining a $5 million Share Purchase Plan for eligible shareholders and a C$15 million Canadian flow-through share offer, aimed at funding key development and exploration activities at its Green Bay Copper-Gold Project.